Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials

Critical Reviews in Oncology/Hematology

Volumn 90, Issue 3, 2014, Pages 253-261

  Morgan, Charity J ^a   Oh, William K ^b   Naik, Gurudatta ^c   Galsky, Matthew D ^b   Sonpavde, Guru ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Mt Sinai Tisch Cancer Institute   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

Clinical trial; Meta analysis; Metastatic castration resistant prostate cancer; Prednisone; Randomized; Survival; Toxicities

Indexed keywords

PREDNISONE; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; HEALTH STATUS; HUMAN; META ANALYSIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; OVERALL SURVIVAL; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; MALE; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; ODDS RATIO; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84899973465     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.12.001     Document Type: Review

References (28)

1. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1996, 14:1756-1764.
2. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1999, 17:2506-2513.
3. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England Journal of Medicine 2004, 351:1502-1512.
4. Kelly W.K., Halabi S., Carducci M., et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2012, 30:1534-1540.
5. de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
6. de Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. The New England Journal of Medicine 2011, 364:1995-2005.
7. Ryan C.J., Smith M.R., de Bono J.S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England Journal of Medicine 2013, 368:138-148.
8. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England Journal of Medicine 2010, 363:411-422.
9. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996, 17:1-12.
10. Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology 2009, 62:e1-e34.
11. Schwarzer G. Meta-Analysis with R. R package version 2.3-0 2013, http://CRANR-projectorg/package=meta.
12. Viechtbauer W. Conducting meta-analyses in R with the metafor package. Journal of Statistical Software 2010, 36(3):1-48.
13. DerSimonian R., Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986, 7:177-188.
14. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. British Medical Journal 2003, 327:557-560.
15. Scher H.I., Jia X., Chi K., et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011, 29:2191-2198.
16. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England Journal of Medicine 2004, 351:1513-1520.
17. Fossa S.D., Slee P.H., Brausi M., et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2001, 19:62-71.
18. Higano C.S., Saad F., Curti B.D., et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancers Symposium 2009.
19. Small E., Demkow T., Gerritsen W.R., et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Proceedings Genitourinary Cancer Symposium 2009, [abstract 7].
20. Cooper H., Hedges L. The handbook of research synthesis 1994, Russell Sage, New York.
21. Small E.J., Lance R.S., Redfern C.H., et al. A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology 2013, 31. [suppl; abstr 5047].
22. Scher H.I., Fizazi K., Saad F., et al. Association of baseline corticosteroid with outcomes in a multivariate analysis of the phase 3 affirm study of enzalutamide (ENZA), an androgen receptor signaling inhibitor (ARSI). ESMO Congress 2012.
23. Montgomery R.B., Kheoh T., Molina A., et al. Effect of corticosteroid use at baseline on overall survival in patients receiving abiraterone acetate: results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer post-docetaxel. Journal of Clinical Oncology 2013, 31. [suppl; abstr 5014].
24. Sternberg C.N., Petrylak D.P., Sartor O., et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2009, 27:5431-5438.
25. Sartor O., Weinberger M., Moore A., Li A., Figg W.D. Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 1998, 52:252-256.
26. Tannock I., Gospodarowicz M., Meakin W., Panzarella T., Stewart L., Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1989, 7:590-597.
27. Yano A., Fujii Y., Iwai A., Kageyama Y., Kihara K. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2006, 12:3003-3009.
28. Otto K., Vander Griend D., Conzen S., Szmulewitz R. Glucocorticoid receptor-mediated cell survival following androgen receptor blockade in castrate-resistant prostate cancer. Cancer Research 2012, 72(April (8 Suppl. 1)).